Pal A. Holme

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Interleukin-17-associated inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia.

Interleukin-17-associated inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia.

Journal: Haematologica

Published: April 09, 2026

Von Willebrand disease.

Von Willebrand disease.

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: March 27, 2026

Title Not Found

Title Not Found

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: March 27, 2026

Post Hoc Analyses of A-SURE and PREVENT Confirm the Effectiveness of rFVIIIFc Prophylaxis Across All Ages, BMIs, Severities, and Inhibitor Histories.

Post Hoc Analyses of A-SURE and PREVENT Confirm the Effectiveness of rFVIIIFc Prophylaxis Across All Ages, BMIs, Severities, and Inhibitor Histories.

Journal: TH open : companion journal to thrombosis and haemostasis

Published: February 27, 2026

Comparison of IPAQ-SF Self-Reported and Fitbit-Measured Physical Activity in Young People With Haemophilia.

Comparison of IPAQ-SF Self-Reported and Fitbit-Measured Physical Activity in Young People With Haemophilia.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 17, 2025

Safety and efficacy of daratumumab in immune thrombocytopenia.

Safety and efficacy of daratumumab in immune thrombocytopenia.

Journal: Blood advances

Published: May 28, 2025

Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study.

Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: March 31, 2025

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post-Marketing Study.

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post-Marketing Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 17, 2025

Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

Journal: Drugs in R&D

Published: October 25, 2024

Human papilloma virus vaccine induced thrombocytopenia accompanied by a wide spectrum of reversible inflammatory responses - a case report.

Human papilloma virus vaccine induced thrombocytopenia accompanied by a wide spectrum of reversible inflammatory responses - a case report.

Journal: Scandinavian journal of clinical and laboratory investigation

Published: September 12, 2024

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy.

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy.

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: August 19, 2024

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

Journal: Drugs in R&D

Published: July 18, 2024

Showing 1-12 of 96

Last Updated: 09/26/2026